The present study is the first to demonstrate antiangiogenic properties of a MAGL inhibitor, and thus degradation inhibitor of the endocannabinoid 2-AG, under hypoxic conditions due to decreased expression of VEGF in lung cancer cells and subsequently diminished activation of VEGFR2 in human endothelial cells. The gene discussed is MGLL; the disease is lung cancer.